SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Guangzhou Innogen Subsidiary Licenses Efsubaglutide Alfa to Arcera

The licensing deal is potentially worth over US$1 billion.

Related stories